FDA reinstates generic drug policy group let go in April firings
The FDA has reinstated a generic drug policy team that was laid off in April, one that was at least partially responsible for leading the agency to a record number of new generic drug approvals ...
View ArticleNational Resilience to shutter six manufacturing sites amid biotech slowdown
The venture-backed drug manufacturing company National Resilience said it will close six underutilized sites in a significant reset of its ambitions to grow into a major player in biopharmaceutical...
View ArticleTrump administration removes all members of CDC vaccine board
HHS Secretary Robert F. Kennedy Jr. removed all members of the CDC’s vaccine advisory panel, known as the Advisory Committee on Immunization Practices, an extraordinary move to gut years of vaccine...
View ArticleOdyssey Therapeutics withdraws IPO plans as public markets remain frozen
Immunology biotech Odyssey Therapeutics has withdrawn its plans to go public via an IPO, according to a regulatory filing on Monday evening. The biotech didn't appear to immediately need the cash....
View ArticleRecursion to lay off 20% of staff, a month after slashing its pipeline
Recursion, one of the original AI-driven biotech companies that merged with its peer Exscientia last year, is laying off about 20% of its employees. The Salt Lake City-based biotech disclosed the job...
View ArticleExclusive: Post-Lilly deal, Scorpion crew carries on with $177M at Antares
BOSTON – Antares Therapeutics is in a unique position. The Boston and South San Francisco biotech said Tuesday it's raised a $177 million Series A, but it's much further along than most drug developers...
View ArticleFormer a16z biotech investment leader Vijay Pande exits the VC firm
Vijay Pande is leaving Andreessen Horowitz after 11 years at the VC firm, he wrote in Monday evening posts on LinkedIn and X. His departure comes six months after he was ...
View ArticleGoodRx goes toe-to-toe with Hims, Ro as it pushes into ED treatment
GoodRx, the company that offers drug discounts at the pharmacy counter, now wants to help patients tackle erectile dysfunction. The company on Tuesday said it’s offering subscriptions that include a...
View ArticleRebooting dead human brains, biotech seeks to reinvent drug testing work
NEW HAVEN, CT — In an old brick building across the street from Yale School of Medicine, a jumble of plastic tubes rhythmically pulse and sway as they pump fluids in and out of a ...
View ArticleNext in line
Last week, Omada Health made its public market debut, just two weeks after Hinge Health — the first initial public offerings digital health has seen in ...
View ArticleInsmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues
Plus, news about AriBio, Arcera, Molecular Partners, Valneva, MacroGenics, Sagard Healthcare Partners, Quell Therapeutics, AstraZeneca, Guardian Bio, Lucy Therapeutics, Argenica, and Gilead’s Tmunity:...
View ArticleEndpoints livestream: RFK Jr. fired the CDC's vaccine panel, and what happens...
Today on Post-Hoc Live, we’re going to dig into HHS Secretary Robert F. Kennedy Jr.’s controversial decision to fire all members of the CDC’s expert vaccine panel, known as ACIP. Yesterday, Kennedy...
View ArticleFDA places hold on Gilead's studies of HIV treatment pill combo
The FDA ordered Gilead to pause studies of two long-acting HIV pills after "a subset of participants" experienced decreases in their immune cell counts, which could be a sign that the immune system is...
View ArticleFDA chief Makary says he wasn’t involved in decision to fire ACIP members
FDA Commissioner Marty Makary said he wasn’t involved in HHS Secretary Robert F. Kennedy Jr.'s decision to fire every member of a key CDC expert panel that guides national vaccine policy. Makary's...
View ArticleArgenx says its drug Vyvgart looks promising in two more autoimmune diseases
The Dutch biotech argenx has big plans for its autoimmune disease drug Vyvgart, which is approved for three conditions and is being tested in a dozen more. On Tuesday evening, it announced ...
View ArticleVertex lays off 125 workers after type 1 diabetes cell therapy failed study...
Vertex Pharmaceuticals is letting go of 125 employees in Rhode Island after a clinical disappointment for its Phase 1/2 type 1 diabetes program. The Boston-based drugmaker is consolidating three of its...
View ArticleSpliceBio gets $135M shortly after starting first clinical trial
In the difficult field of gene therapies, some biotech startups are still reeling in large amounts of capital. Barcelona-based SpliceBio is the latest. The 40-employee upstart bagged a $135 million...
View ArticleBasecamp Research CEO on fixing the 'data wall' in AI bio
From hiking through rainforests to diving into the ocean's depths, the scientist-explorers of Basecamp Research have scoured the Earth's extremes to sample and study biological life. The research...
View ArticleBMS’ RayzeBio bags rights for Philochem’s radiopharma asset for $350M upfront
Bristol Myers Squibb’s subsidiary RayzeBio is spending $350 million upfront to license an early-stage radiopharmaceutical candidate for prostate cancer from Philochem. RayzeBio will get global rights...
View ArticleNovo marks seventh cardiometabolic deal of the year with Deep Apple Therapeutics
Novo Nordisk has been on a dealmaking spree this year to assuage concerns about the future of its obesity and cardiometabolic drugs. The Danish drugmaker's latest partner of choice is Apple Tree ...
View Article